Core Insights - HUTCHMED is presenting new and updated data on its compounds savolitinib, fruquintinib, and surufatinib at the AACR Annual Meeting 2025, highlighting ongoing research and development efforts in oncology [1][2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [11]. - The company has successfully marketed three medicines in China, with its first drug also approved in the US, Europe, and Japan [11]. Product Information - **Savolitinib**: An oral, selective MET tyrosine kinase inhibitor developed in collaboration with AstraZeneca, approved in China for treating advanced or metastatic NSCLC with MET exon 14 skipping alterations [5][6]. - **Fruquintinib**: Undergoing clinical development for various tumor types, including colorectal cancer, and is being studied in combination with other therapies [2][5]. - **Surufatinib**: Currently in clinical trials for advanced neuroendocrine tumors and other cancers, with ongoing studies to assess its efficacy in combination with other treatments [2][3]. Clinical Trials and Research - The **SAVANNAH** study is evaluating the combination of savolitinib and osimertinib in NSCLC patients who have progressed after EGFR TKI treatment, with promising results leading to further Phase III trials [7][9]. - The **SACHI** trial has met its primary endpoint of progression-free survival, supporting the combination of savolitinib and TAGRISSO for specific NSCLC patients [9][10]. - The **SAFFRON** trial is assessing the efficacy of savolitinib plus TAGRISSO against platinum-based chemotherapy in a similar patient population [10]. Market Context - Lung cancer remains the leading cause of cancer death globally, with a significant patient population in China, where over a third of the world's lung cancer patients reside [4]. - Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases, with a notable prevalence of EGFR mutations and MET alterations among patients [4].

Core Insights - IN8bio, Inc. is presenting a novel gamma-delta T cell engager platform at the AACR Annual Meeting 2025, highlighting its potential in cancer immunotherapy [1][2] - The company focuses on developing innovative therapies for cancer and autoimmune diseases using gamma-delta T cells, which have unique properties that may overcome limitations of current therapies [2][4] Company Overview - IN8bio is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell-based immunotherapies for cancer and autoimmune diseases [4] - The lead program, INB-100, targets acute myeloid leukemia by evaluating haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant [4] - The company is also exploring autologous DeltEx DRI gamma-delta T cells for glioblastoma and advancing novel gamma-delta T cell engagers for various oncology and autoimmune indications [4] Presentation Details - The poster presentation titled "A novel gamma-delta T cell engager platform for cancer immunotherapy" will take place on April 30, 2025, during the Immunology/T Cell Engagers and Novel Antibody-Based Therapies session [3] - The presentation will showcase early findings in acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL), supporting the broader strategy of utilizing gamma-delta T cells across multiple cancers [2][3]